Unknown
PHASE4
INTERVENTIONAL
NCT02976675
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency, as well as to study the feasibility of extending the dosing intervals (once per two weeks) of PEG Somatropin Injection.
Interventions
Name:
PEG-somatropin
Type:
BIOLOGICAL
Description:
Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
Name:
PEG-somatropin
Type:
BIOLOGICAL
Description:
Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
Primary Outcomes
Measure:
Ht SDSca
TimeFrame:
Baseline, 4,12,26 weeks after initiating treatment
Description:
Ht SDSca was calculated by dividing the difference between the actual height of a patient and the mean height of the population for that chronological age by the standard deviation (SD) of the height of the population for that chronological age
Trial Information
NCT ID
NCT02976675
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Last Updated
December 15, 2025